From DCAT Value Chain Insights (VCI)
The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the China Pharmaceutical Industry Association (CPIA) organized a China/EU Pharmaceutical Industry Forum on May 16, 2015 in Shanghai, China. The workshop covered a variety of themes, including: an overview of the pharmaceutical industry in China and the European Union (EU); patient access to innovative drugs; the Drug Administration Law (DAL) revision; drug quality; and pharmaceuticals in the environment.
EFPIA’s Chief Economist, Richard Torbett, was scheduled to offer an overview of the pharmaceutical industry in the EU, including the e barriers to access for innovative drugs but also some possible solutions to the challenge of health system sustainability. Anette Hjelmsmark from the EFPIA China regulatory network was scheduled to give a presentation on the EU system for marketing authorization and the enablers facilitating development of medicines, including EFPIA recommendations to separate new drug applications from the clinical trial applications. Bengt Mattson, co-chair of the EFPIA Pharmaceuticals in the Environment (PIE-TF) was to cover expectations from the European industry regarding collaboration on drug quality and the environment. A major theme of his presentation will be the concept of a maturity ladder, which is a step-wise approach of increasing capability.Mr Liu Jihong from the Chinese Food and Drug Administration (CFDA) was scheduled to offer plans for reforming the Chinese Drug Administration Law.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription